BioSpace News Archive

Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, today announced that the Nerivio® prescription wearable recently received Food and Drug Administration (FDA) clearance as a dual-use acute and preventive treatment for migraine with or without aura in people 12 years of age or older.

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Administration (TGA) in Australia.

Voltron Therapeutics, Inc announced that it has signed a new Sponsored Research Agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that primary endpoint results from the RADIANCE II pivotal trial were published in the Journal of the American Medical Association (JAMA).

DiscGenics, Inc. today announced that it will present at Canaccord Genuity’s 18th Annual Musculoskeletal Conference taking place in Las Vegas, NV on Tuesday, March 7, 2023.

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of patient enrollment in the company’s pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance®.

Transcat, Inc. announce that Lee Rudow, President and Chief Executive Officer, and Tom Barbato, Chief Financial Officer, will be available for investor meetings at the Roth Conference on Monday, March 13 and Tuesday, March 14, 2023 at the Ritz Carlton, Laguna Niguel in Dana Point, California.

Spero Therapeutics, Inc. announced that on February 22, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 180,000 restricted stock unit awards to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.

Prometheus Biosciences, Inc. (Nasdaq: RXDX) today reported financial results for the quarter and full-year ended December 31, 2022 and highlighted recent corporate progress.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter and year ended December 31, 2022.